Full Press Release Details
INDIANAPOLIS , March 1, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will showcase results from pivotal Phase 3 data investigating ixekizumab for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis at the 74 th annual meeting of the American Academy of Dermatology (AAD), which will take place March 4-8, 2016 , in Washington, D.C.
A total of 29 abstracts, including three oral presentations, will feature Lilly's ixekizumab data for the treatment of moderate-to-severe plaque psoriasis across a number of areas, including efficacy and safety data at 12 weeks and 60 weeks, patient-reported outcomes and data evaluating the efficacy and safety of ixekizumab compared to etanercept. Two abstracts evaluating the efficacy and safety of ixekizumab for the treatment of active psoriatic arthritis will also be presented.
"Moderate-to-severe plaque psoriasis can significantly impact all aspects of a person's life, including both physical and emotional burdens," said Aarti Shah , Ph.D., Vice President and Global Brand Development Leader, Ixekizumab, Eli Lilly and Company. "We are pleased to bring a comprehensive review of data for ixekizumab to this year's American Academy of Dermatology annual meeting, which we believe highlights the potential for ixekizumab, if approved, to address the challenges faced by people living with this disease and physicians looking to provide a new treatment option for their patients."
Studies, as well as the times and locations of the data sessions, are highlighted below.
Oral Presentations
Saturday, March 5
Monday, March 7
Poster Presentations
Friday, March 4
Sunday, March 6
Monday, March 7
About Ixekizumab Ixekizumab is an IgG4 monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Ixekizumab inhibits the release of pro-inflammatory cytokines and chemokines.
About Moderate-to-Severe Plaque Psoriasis Psoriasis is a chronic, immune disease that affects the skin. 1 It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis affects approximately 125 million people worldwide, approximately 20 percent of whom have moderate-to-severe plaque psoriasis. 1,2 Psoriasis can occur on any part of the body and is associated with other serious health conditions, such as diabetes and heart disease. 1 The most common form of psoriasis, plaque psoriasis, appears as raised, red patches covered with a silvery white buildup of dead skin cells. 1
About Eli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels . P-LLY
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about ixekizumab as a potential treatment for moderate-to-severe plaque psoriasis, and reflects Lilly's current belief. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that ixekizumab will receive additional regulatory approvals or be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
1 Psoriasis media kit. National Psoriasis Foundation website. https://www.psoriasis.org/sites/default/files/for-media/MediaKit.pdf . Accessed February 29, 2016 . 2 Psoriasis. American Academy of Dermatology website. https://www.aad.org/media-resources/stats-and-facts/conditions/psoriasis . Accessed February 29, 2016 .
Refer to: Jen Dial ; [email protected] ; 317-220-1172 (Lilly BioMedicines)
SOURCE Eli Lilly and Company